Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VINORELBINE\VINORELBINE for Non-small cell lung cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 163 adverse event reports in the FDA FAERS database where VINORELBINE\VINORELBINE was used for Non-small cell lung cancer.

Most Reported Side Effects for VINORELBINE\VINORELBINE

Side Effect Reports % Deaths Hosp.
Malignant neoplasm progression 158 11.6% 26 25
Neutropenia 151 11.1% 36 22
Disease progression 105 7.7% 26 14
Death 98 7.2% 98 14
Off label use 94 6.9% 11 31
Nausea 89 6.5% 8 23
Anaemia 88 6.5% 17 21
Drug ineffective 81 6.0% 21 7
Diarrhoea 77 5.7% 14 13
Vomiting 71 5.2% 10 18
Thrombocytopenia 69 5.1% 20 14
Febrile neutropenia 67 4.9% 15 31
Fatigue 66 4.9% 6 15
Dyspnoea 64 4.7% 24 18
Pyrexia 61 4.5% 5 43

Other Indications for VINORELBINE\VINORELBINE

Breast cancer metastatic (171) Breast cancer (106) Hodgkin's disease (99) Product used for unknown indication (95) Her-2 positive breast cancer (86) Lung neoplasm malignant (73) Lung adenocarcinoma (40) Invasive ductal breast carcinoma (33) Diffuse large b-cell lymphoma (28) Chemotherapy (27)

Other Drugs Used for Non-small cell lung cancer

NIVOLUMAB (9,987) CARBOPLATIN (7,939) PEMBROLIZUMAB (6,893) OSIMERTINIB (6,358) PEMETREXED (5,179) PACLITAXEL (4,609) ATEZOLIZUMAB (4,459) BEVACIZUMAB (4,136) DURVALUMAB (3,396) ERLOTINIB (3,359)

Related Pages

VINORELBINE\VINORELBINE Full Profile All Non-small cell lung cancer Drugs VINORELBINE\VINORELBINE Demographics VINORELBINE\VINORELBINE Timeline